SEC Tracker
Get the app
MNKD · XBRL financial data

MannKind financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (MNKD's year ends in late December)

In millions of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Revenue from contracts with customers5158*66727077*787782112*90109
Cost of goods and services sold46*4635*454year only814
Selling, general and administrative—year only22242424*25322958*5458
General and administrative1110*111311———————
Total operating expenses1418*19201820*—21—year only—30
Operating income (loss)58*17171326*22519(8)*(2)(0)
Interest income22*3333*2232*11
Interest expense33*3622*5018*712
Other income (expense)0(0)*——00*———year only(3)(5)
Income tax expense (benefit)02*0011*00(0)(5)*0(0)
Net income (loss)21*11(2)127*1318(16)*(17)(19)
Earnings per share, basic USD per share0.010.01*0.04(0.01)0.040.03*0.040.000.03(0.05)*(0.05)(0.06)
Earnings per share, diluted USD per share0.010.01*0.04(0.01)0.040.03*0.040.000.03(0.05)*(0.05)(0.06)
Weighted average shares, basic millions of shares269270*270273275279*303305307307*308309
Weighted average shares, diluted millions of shares324215*325273285253*321311312313*308309

Balance sheet

CSV

Fiscal quarters (MNKD's year ends in late December)

In millions of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Cash and cash equivalents832381939762464757127755353
Short-term investments5857107151189151134122133968158
Accounts receivable221520231812292717382843
Inventory272926252728292827354944
Prepaid and other current assets363536303131344454474047
Total current assets226373383326328268274279359292251246
Property and equipment, net808484858585848383828385
Right-of-use asset55441413131211121111
Goodwill222222222686868
Total assets320475481444464394410412495792744732
Accounts payable171071067510791611
Accrued liabilities324242413740403131655961
Total current liabilities96104100807282116112109171135143
Lease liability, non-current44431212111110111010
Total liabilities572721711670674473469467539843804800
Accumulated deficit(3,231)(3,229)(3,219)(3,221)(3,209)(3,202)(3,189)(3,188)(3,180)(3,196)(3,213)(3,232)
Total stockholders' equity(252)(246)(230)(226)(210)(79)(59)(55)(45)(51)(59)(67)
Total liabilities and equity320475481444464394410412495792744732
Common shares outstanding (cover page) millions of shares270270272275276304304307307308309322

Cash flows

CSV

Fiscal quarters (MNKD's year ends in late December)

In millions of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Net income (loss)21*11(2)127*1318(16)*(17)(19)
Stock-based compensation5*4*46*5*6*58*4*7*610*
Net cash from operating activities9*22*74*9*23*(6)9*24*(8)*(5)(18)*
Purchases of property and equipment11*6*23*1*3*01*1*2*25*
Net cash from investing activities(12)*(8)*(48)(55)*(41)*48*66*(25)*(292)*1918*
Net cash from financing activities(0)*142*(3)(45)*(2)*(87)*1(6)*72*247*(35)1*
Net change in cash(3)*155*(45)(96)*(34)*(16)*110*70*(53)*(22)0*

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($M)Revenue, quarter ($M)Operating cash flow, quarter ($M)Shares outstandingRunwayQuarter
Mannkind53109(18)*321.5M6.0 quarters 10-QJun 30, 2026
Schrodinger28859(34)*not reported12.1 quarters 10-QJun 30, 2026
Spyre Therapeutics83not reported(77)*95.0M15.7 quarters 10-QSep 30, 2026
Novavax19157(73)*164.9M9.9 quarters 10-QJun 30, 2026
Innoviva57012052*72.2M— 10-QJun 30, 2026
Harrow8471(9.8)*37.5M8.6 quarters 10-QJun 30, 2026
Aurinia Pharmaceuticals468446*134.0M— 10-QSep 30, 2026
Ani Pharmaceuticals36026657*not reported— 10-QJun 30, 2026
Celldex Therapeutics470(57)*78.5M12.5 quarters 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.